GERN
Price
$3.90
Change
-$0.00 (-0.00%)
Updated
May 16, 6:59 PM EST
76 days until earnings call
RNA
Price
$28.71
Change
-$0.80 (-2.71%)
Updated
May 16, 6:59 PM EST
81 days until earnings call
Ad is loading...

GERN vs RNA

Header iconGERN vs RNA Comparison
Open Charts GERN vs RNABanner chart's image
Geron
Price$3.90
Change-$0.00 (-0.00%)
Volume$3.43M
CapitalizationN/A
Avidity Biosciences
Price$28.71
Change-$0.80 (-2.71%)
Volume$607.9K
CapitalizationN/A
View a ticker or compare two or three
GERN vs RNA Comparison Chart

Loading...

RNADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
GERN vs. RNA commentary
May 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and RNA is a Hold.

COMPARISON
Comparison
May 17, 2024
Stock price -- (GERN: $3.90 vs. RNA: $29.51)
Brand notoriety: GERN and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 38% vs. RNA: 153%
Market capitalization -- GERN: $2.31B vs. RNA: $2.82B
GERN [@Biotechnology] is valued at $2.31B. RNA’s [@Biotechnology] market capitalization is $2.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $592.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 1 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • GERN’s FA Score: 1 green, 4 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, GERN is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNA’s TA Score shows that 4 TA indicator(s) are bullish.

  • RNA’s TA Score: 4 bullish, 4 bearish.

Price Growth

GERN (@Biotechnology) experienced а +0.52% price change this week, while RNA (@Biotechnology) price change was +13.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.45%. For the same industry, the average monthly price growth was +4.26%, and the average quarterly price growth was +63.16%.

Reported Earning Dates

GERN is expected to report earnings on Aug 01, 2024.

RNA is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+2.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for GERN with price predictions.
OPEN
A.I.dvisor published
a Summary for RNA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RNA($2.82B) has a higher market cap than GERN($2.31B). RNA YTD gains are higher at: 226.077 vs. GERN (84.834).
GERNRNAGERN / RNA
Capitalization2.31B2.82B82%
EBITDAN/AN/A-
Gain YTD84.834226.07738%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
GERN: Fundamental Ratings
GERN
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
PROFIT vs RISK RATING
1..100
30
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
76
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RNA
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 4 days ago
80%
View a ticker or compare two or three
Ad is loading...
RNADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CAXAX17.970.02
+0.11%
Catalyst/MAP Global Equity A
MWOKX65.79-0.04
-0.06%
MFS Global Growth R6
PRPHX53.91-0.18
-0.33%
Permanent Portfolio Permanent C
FBGRX206.08-0.85
-0.41%
Fidelity Blue Chip Growth
PUVCX39.99-0.20
-0.50%
Putnam International Capital Opp C